Update on Antithrombotic Therapy New Anticoagulants

被引:192
作者
Eikelboom, John W. [2 ]
Weitz, Jeffrey I. [1 ,2 ,3 ]
机构
[1] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
[3] Dept Biochem & Med Sci, Hamilton, ON, Canada
关键词
anticoagulants; antithrombotic therapy; ACUTE CORONARY SYNDROMES; TOTAL HIP-REPLACEMENT; DIRECT THROMBIN INHIBITOR; TOTAL KNEE REPLACEMENT; ORAL DIRECT THROMBIN; FACTOR-XA INHIBITOR; MOLECULAR-WEIGHT HEPARIN; VITAMIN-K ANTAGONISTS; NON-INFERIORITY TRIAL; FACTOR-IXA ACTIVITY;
D O I
10.1161/CIRCULATIONAHA.109.853119
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1523 / 1532
页数:10
相关论文
共 49 条
[11]   Otamixaban in acute coronary syndromes [J].
Eikelboom, John W. ;
Weitz, Jeffrey I. .
LANCET, 2009, 374 (9692) :762-764
[12]   Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].
Eriksson, B. I. ;
Dahl, O. E. ;
Rosencher, N. ;
Kurth, A. A. ;
Van Dijk, N. ;
Frostick, S. P. ;
Kalebo, P. ;
Christiansen, A. V. ;
Hantel, S. ;
Hettiarachchi, R. ;
Schnee, J. ;
Buller, H. R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185
[13]   Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty [J].
Eriksson, Bengt I. ;
Borris, Lars C. ;
Friedman, Richard J. ;
Haas, Sylvia ;
Huisman, Menno V. ;
Kakkar, Ajay K. ;
Bandel, Tiemo J. ;
Beckmann, Horst ;
Muehlhofer, Eva ;
Misselwitz, Frank ;
Geerts, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) :2765-2775
[14]   Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].
Eriksson, Bengt I. ;
Dahl, Ola E. ;
Rosencher, Nadia ;
Kurth, Andreas A. ;
van Dijk, C. Niek ;
Frostick, Simon P. ;
Prins, Martin H. ;
Hettiarachchi, Rohan ;
Hantel, Stefan ;
Schnee, Janet ;
Bueller, Harry R. .
LANCET, 2007, 370 (9591) :949-956
[15]   A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [J].
Eriksson, Bengt I. ;
Borris, Lars C. ;
Dahl, Ola E. ;
Haas, Sylvia ;
Huisman, Menno V. ;
Kakkar, Ajay K. ;
Muehlhofer, Eva ;
Dierig, Christoph ;
Misselwitz, Frank ;
Kalebo, Peter .
CIRCULATION, 2006, 114 (22) :2374-2381
[16]   Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development [J].
Eriksson, Bengt I. ;
Quinla, Datfiel J. ;
Weitz, Jeffrey I. .
CLINICAL PHARMACOKINETICS, 2009, 48 (01) :1-22
[17]   Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement [J].
Eriksson, BI ;
Borris, L ;
Dahl, OE ;
Haas, S ;
Huisman, MV ;
Kakkar, AK ;
Misselwitz, F ;
Kälebo, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (01) :121-128
[18]   A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].
Eriksson, BI ;
Dahl, OE ;
Büller, HR ;
Hettiarachchi, R ;
Rosencher, N ;
Bravo, ML ;
Ahnfelt, L ;
Piovella, F ;
Stangier, J ;
Kälebo, P ;
Reilly, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111
[19]   Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement:: BISTRO I [J].
Eriksson, BI ;
Dahl, OE ;
Ahnfelt, L ;
Kälebo, P ;
Stangier, J ;
Nehmiz, G ;
Hermansson, K ;
Kohlbrenner, V .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) :1573-1580
[20]   Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran [J].
Ezekowitz, Michael D. ;
Connolly, Stuart ;
Parekh, Amit ;
Reilly, Paul A. ;
Varrone, Jeanne ;
Wang, Susan ;
Oldgren, Jonas ;
Themeles, Ellison ;
Wallentin, Lars ;
Yusuf, Salim .
AMERICAN HEART JOURNAL, 2009, 157 (05) :805-810